目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T0153 | HIF/HIF Prolyl-Hydroxylase HIV Protease Reverse Transcriptase Nrf2 HIF | ||
Oltipraz (RP 35972) 是一种 Nrf2的强效激活剂。它时间依赖性地抑制 HIF-1α激活,IC50为 10 μM,浓度 ≥ 10 μM 时完全消除 HIF-1α诱导。 | |||
T3743 | Antioxidant Nrf2 Endogenous Metabolite | ||
4-hydroxyphenylacetic acid (parahydroxy phenylacetate) 是主要的微生物群衍生的多酚代谢物,能够诱导Nrf2表达,具有抗氧化作用。 | |||
T1558 | Apoptosis Mitophagy IκB/IKK Lipoxygenase Sirtuin COX NADPH DNA/RNA Synthesis Nrf2 Antibacterial Antibiotic Autophagy Antifungal | ||
Resveratrol (SRT 501) 属于多酚类天然产物,是一种植物抗毒素,具有抗氧化和化学预防活性。Resveratrol 的靶点广泛,包括 COX、SIRT、LOC 等。Resveratrol 可以诱导细胞自噬和凋亡。 | |||
T2794 | TNF NF-κB Nrf2 | ||
Astilbin (Neoastilbin) 是在圣约翰草和中药草药制剂中发现的一种黄酮类天然产物,抑制TNF-α表达和NF-κB 活化,可增强NRF2活化。 | |||
T0973L | Nrf2 Endogenous Metabolite | ||
Pyridoxine hydrochloride (Vitamin B6) 是一种吡啶衍生物。在于阿尔茨海默病细胞模型中,通过 Nrf-2/HO-1 途径发挥抗氧化作用。 | |||
T6165 | Apoptosis IκB/IKK Ferroptosis Nrf2 Autophagy | ||
Bardoxolone Methyl (TP-155) 是一种合成的三萜类化合物,作为 Nrf2通路的激活剂和 NF-κB 途径的抑制剂,具有潜在的抗肿瘤和抗炎活性。 | |||
TP2109 | Nrf2 | ||
TAT-14 是 由14 个氨基酸组成的多肽,是 Nrf2激活因子,表现出抗炎活性。它通过靶向 Nrf2 上 Keap1 的结合位点而非 Nrf2 mRNA 表达来提高 Nrf2 蛋白水平。 | |||
T63987 | |||
Keap1-Nrf2-IN-14 是一种 KEAP1-NRF2 抑制剂,可有效破坏 KEAP1-NRF2 相互作用 (IC50: 75 nM),其对 KEAP1的 Kd=24 nM。Keap1-Nrf2-IN-14 可诱导 NRF2 靶基因表达,能够提高下游的抗氧化和抗炎效果。Keap1-Nrf2-IN-14 能够用于研究氧化应激相关炎症。 | |||
T1516 | Mitophagy Epigenetic Reader Domain Ferroptosis Influenza Virus Nrf2 Histone Acetyltransferase HDAC Autophagy | ||
Curcumin (Natural Yellow 3) 属于酚类天然产物,是一种组蛋白乙酰化转移酶 p300/CREB 的抑制剂 (IC50=25 μM),具有特异性。Curcumin 具有抗肿瘤、抗炎和抗氧化等多种药理活性。 | |||
T1368 | Apoptosis Antioxidant Nrf2 | ||
Methyl 3,4-dihydroxybenzoate (Protocatechuic acid methyl ester) 是绿茶中发现的主要代谢产物,是一种多酚,有抗氧化和抗炎作用。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-02101 | KEAP1 Protein, Human, Recombinant (His & GST & Avi) | Human | Baculovirus-Insect Cells | ||
Kelch-like ECH-associated protein 1, also known as a cytosolic inhibitor of Nrf2, Kelch-like protein 19, KEAP1, and INRF2, is a cytoplasm and nucleus protein that contains one BACK (BTB/Kelch associated) domain, one BTB (POZ) domain, and six Kelch repeats. KEAP1 / INRF2 is broadly expressed, with the highest levels in skeletal muscle. KEAP1 / INRF2 is a key regulator of the NRF2 transcription factor, which transactivates the antioxidant response element (ARE) and upregulates numerous proteins involved in antioxidant defense. Under basal conditions, KEAP1 / INRF2 targets NRF2 for ubiquitination and proteolytic degradation and as such is responsible for the rapid turnover of NRF2. KEAP1 / INRF2 retains NFE2L2 / NRF2 in the cytosol. KEAP1 / INRF2 functions as a substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1. It targets NFE2L2 / NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression. KEAP1 / INRF2 may also retain BPTF in the cytosol. It targets PGAM5 for ubiquitination and degradation by the proteasome.
|
|||||
TMPY-03888 | KEAP1 Protein, Human, Recombinant (His & GST) | Human | Baculovirus-Insect Cells | ||
Kelch-like ECH-associated protein 1, also known as a cytosolic inhibitor of Nrf2, Kelch-like protein 19, KEAP1, and INRF2, is a cytoplasm and nucleus protein that contains one BACK (BTB/Kelch associated) domain, one BTB (POZ) domain, and six Kelch repeats. KEAP1 / INRF2 is broadly expressed, with the highest levels in skeletal muscle. KEAP1 / INRF2 is a key regulator of the NRF2 transcription factor, which transactivates the antioxidant response element (ARE) and upregulates numerous proteins involved in antioxidant defense. Under basal conditions, KEAP1 / INRF2 targets NRF2 for ubiquitination and proteolytic degradation and as such is responsible for the rapid turnover of NRF2. KEAP1 / INRF2 retains NFE2L2 / NRF2 in the cytosol. KEAP1 / INRF2 functions as a substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1. It targets NFE2L2 / NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression. KEAP1 / INRF2 may also retain BPTF in the cytosol. It targets PGAM5 for ubiquitination and degradation by the proteasome.
|
|||||
TMPY-03432 | KEAP1 Protein, Human, Recombinant | Human | Baculovirus-Insect Cells | ||
Kelch-like ECH-associated protein 1, also known as a cytosolic inhibitor of Nrf2, Kelch-like protein 19, KEAP1, and INRF2, is a cytoplasm and nucleus protein that contains one BACK (BTB/Kelch associated) domain, one BTB (POZ) domain, and six Kelch repeats. KEAP1 / INRF2 is broadly expressed, with the highest levels in skeletal muscle. KEAP1 / INRF2 is a key regulator of the NRF2 transcription factor, which transactivates the antioxidant response element (ARE) and upregulates numerous proteins involved in antioxidant defense. Under basal conditions, KEAP1 / INRF2 targets NRF2 for ubiquitination and proteolytic degradation and as such is responsible for the rapid turnover of NRF2. KEAP1 / INRF2 retains NFE2L2 / NRF2 in the cytosol. KEAP1 / INRF2 functions as a substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1. It targets NFE2L2 / NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression. KEAP1 / INRF2 may also retain BPTF in the cytosol. It targets PGAM5 for ubiquitination and degradation by the proteasome.
|
|||||
TMPH-01788 | NFE2L2 Protein, Human, Recombinant (His) | Human | E. coli | ||
Transcription factor that plays a key role in the response to oxidative stress: binds to antioxidant response (ARE) elements present in the promoter region of many cytoprotective genes, such as phase 2 detoxifying enzymes, and promotes their expression, thereby neutralizing reactive electrophiles. In normal conditions, ubiquitinated and degraded in the cytoplasm by the BCR(KEAP1) complex. In response to oxidative stress, electrophile metabolites inhibit activity of the BCR(KEAP1) complex, promoting nuclear accumulation of NFE2L2/NRF2, heterodimerization with one of the small Maf proteins and binding to ARE elements of cytoprotective target genes. The NFE2L2/NRF2 pathway is also activated in response to selective autophagy: autophagy promotes interaction between KEAP1 and SQSTM1/p62 and subsequent inactivation of the BCR(KEAP1) complex, leading to NFE2L2/NRF2 nuclear accumulation and expression of cytoprotective genes. May also be involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region. Plays also an important role in the regulation of the innate immune response and antiviral cytosolic DNA sensing. It is a critical regulator of the innate immune response and survival during sepsis by maintaining redox homeostasis and restraint of the dysregulation of proinflammatory signaling pathways like MyD88-dependent and -independent and TNF-alpha signaling. Suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription and the induction of IL6. Binds to the proximity of proinflammatory genes in macrophages and inhibits RNA Pol II recruitment. The inhibition is independent of the NRF2-binding motif and reactive oxygen species level. Represses antiviral cytosolic DNA sensing by suppressing the expression of the adapter protein STING1 and decreasing responsiveness to STING1 agonists while increasing susceptibility to infection with DNA viruses. Once activated, limits the release of pro-inflammatory cytokines in response to human coronavirus SARS-CoV-2 infection and to virus-derived ligands through a mechanism that involves inhibition of IRF3 dimerization. Also inhibits both SARS-CoV-2 replication, as well as the replication of several other pathogenic viruses including Herpes Simplex Virus-1 and-2, Vaccinia virus, and Zika virus through a type I interferon (IFN)-independent mechanism.
|